



At last, rapid analgesia with rapid recovery.

New

Trademarks

RAPIDEN

(alfentanil)

minute by minute control of short procedures

ABRIDGED PRODUCT INFORMATION

Causes of headache: Doseage and administration: Dosage should be adjusted for individual needs. Methylcholine or aspirin, pregnancy or lactation. children. **Precautions:** Warn patients that certain chronic disorders (epilepsy or parkinsonism, Peptic ulcer, hemorrhage and perforation of the bowel, etc.) may be aggravated by the use of existing but controlled infection during prolonged use. Caution in use in presence of existing but controlled infection during prolonged use. Caution in use in presence of existing but controlled infection during prolonged use. Confusion, stupor, convulsions, coma, drowsiness, peripheral neuropathy, pruritis, and rashes.



Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

284 per 100

Lasting relief that more patients stay with

Indocid®-R

Sustained-release indomethacin

There is no substitute for success

96%

in urinary tract infections **Septin b.d.**

Trade Mark

Prescribing Information

Uses: Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

Dosage: *Septin Forte Tablets:* over 12 years, one twice daily; *Septin Tablets/Septin Dispersible Tablets:* over 12 years, two twice daily; children 6 to 12 years, one twice daily; *Septin Suspension:* over 12 years, 10ml Adult twice daily; children 6 to 12 years, 10ml Paediatric twice daily; 6 months to 6 years, 5ml Paediatric twice daily; 6 weeks to 6 months, 2.5ml Paediatric twice daily.

Contra-indications: Septin is contra-indicated in patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency. Septin should not be given to patients hypersensitive to sulphonamides or co-trimoxazole; should not be given during pregnancy or to neonates.

Precautions: In cases of renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained.

I. Gower, P.E. and Tasker, P.R.W. (1976), *Brit. Med. J.*, 1, 684. Double-blind comparison of Septin with cephalexin in 93 women with acute UTI. After two weeks, 96% of Septin-treated patients were infection-free, compared with 68% of cephalexin-treated patients.

Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septin to patients receiving oral anti-coagulants of the coumarin group, pyrimethamine, sulphonylureas, or phenytoin.

Warnings and Adverse Effects: Occasionally nausea, vomiting, diarrhoea, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

Further information is available on request.

Wellcome Medical Division

The Wellcome Foundation Ltd, Crewe, Cheshire.



Wellcome

Presentations:

| | Product Licence | Formulation | Base NHS Cost |
|------------------------------|-----------------|---|-----------------|
| Septin Forte Tablets | PL3/0121 | 160mg Trimethoprim BP 800mg Sulphamethoxazole BP | £3.90 for 10 |
| Septin Tablets | PL3/0109 | 80mg TMP 400mg SMX | £2.27 for 20 |
| Septin Dispersible Tablets | PL3/0099 | 80mg TMP 400mg SMX | £2.42 for 20 |
| Septin | PL3/5223 | 80mg TMP 400mg SMX in 5ml | £3.32 for 100ml |
| Adult Suspension | | 40mg TMP 200mg SMX in 5ml | £2.00 for 100ml |
| Septin Paediatric Suspension | PL3/5222 | 20mg TMP 100mg SMX in 5ml | £0.69 for 100ml |
| Septin Paediatric Tablets | PL3/0108 | 20mg TMP 100mg SMX | £0.69 for 20 |

HOW TO DO IT

Every doctor knows the sinking sensation induced by waiting one's turn for an examination viva and the social anxieties of changing jobs. The misery of first night nerves does not, however, disappear with time: each decade brings new challenges. On these occasions—chairing a committee, giving evidence in court, appearing on television—practical tips can be enormously helpful. The same is true of the many skills not taught in medical school—how to lecture, referee papers, edit, or use a library. All these and many more nuggets of down-to-earth advice have been collected from past issues of the *BMJ* to form a compendium for the novice—whatever his or her age or seniority.

Price: Inland £4.50
 Overseas £7.00/USA\$13.00
 (Inland £4.00;
 Overseas £6.50/USA\$12.00
 to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now
 From: The Publisher
 British Medical Journal
 BMA House
 Tavistock Square
 London WC1H 9JR
 or any leading bookseller

HOW TO DO IT

Chair a committee;
 Be a dictator;
 Organise an international conference;
 Take an examination paper;
 Give evidence;
 Be a reporter;
 Give a library;
 Improve a student's presentation;
 Organise a medical meeting;
 Chair a conference;
 Interviewed;
 Survive as an editor;
 Give a paper;
 Construct an editorial;
 Attend an inquiry;
 Apply for a grant;
 Extend an invitation;
 Examine a grant application;
 Write a research paper;
 Plan a research project;
 Write a book;

“ . . . a tribute to their excellence that on rereading they did not pall. It will make a useful present for one's favourite houseman or registrar.”
NZ Med J 1980; 91: 73

“It is a joy to read . . . All in all, this book can be highly recommended.”
Med J Aust 1980; 1: 680



Helps your patient control their disease. Helps reduce your costs.

Of the many thousands of breast cancer patients being treated with 'Nolvadex', one in three is receiving 40mg daily, often in the form of two 10mg tablets b.d.

Now ICI have introduced 'Nolvadex' Forte, enabling you to prescribe a more convenient, once-daily regimen for these patients, with the likelihood of better

compliance and, therefore, better control.

There is also a 20% cost advantage in prescribing 'Nolvadex' Forte rather than 4 x 'Nolvadex' 10mg.

To ensure that your patient receives 'Nolvadex' Forte in a factory-sealed patient pack, please prescribe in multiples of 30.

New

Nolvadex Forte 
ICI tamoxifen

40mg once daily in breast cancer

Prescribing Notes. **Uses** The treatment of breast cancer. **Presentation** White tablet containing tamoxifen 40mg. **Dosage/administration** Dose range is 20 to 40mg daily, as single dose. **Contraindications, warnings etc.** Not to be given during pregnancy; premenopausal patients must be examined before treatment to exclude possibility of pregnancy. **Side effects** 'Nolvadex' Forte suppresses menstruation in some premenopausal patients. Reversible cystic ovarian swellings have occurred very occasionally in premenopausal patients receiving 80mg daily. A small number of patients have developed hypercalcaemia on initiation of therapy. Reported side effects include hot flushes, vaginal bleeding, pruritus vulvae; gastrointestinal intolerance, tumour flare, light-headedness, fluid retention;

transient falls in platelet count. A few cases of visual disturbance, corneal changes and/or retinopathy have been described, mainly following long-term high dosage. Severe side effects may sometimes be controlled by dosage reduction; otherwise, treatment may need to be stopped. **Overdosage** Theoretically, overdosage would cause antioestrogenic effects. Extreme overdosage (eg 100 times daily dosage) may produce oestrogenic effects. No specific antidote. **Packaging** Containers of 30 tablets. **Product licence no.** 0029/0176. **Basic NHS price** £27.14 per pack of 30. 'Nolvadex' is the trademark for ICI tamoxifen. Full information is available upon request. Imperial Chemical Industries PLC, Pharmaceuticals Division, Alderley House, Alderley Park, Macclesfield, Cheshire SK10 4TF 

GUAM

Terra firma

Proven effective over seven years of widespread clinical experience, 'Tagamet' is a known quantity in gastric ulcer treatment.

With 'Tagamet', 25 million patients ahead of the less experienced newcomers, you're on familiar ground.

Tagamet

cimetidine

THOROUGHLY EXPLORED

It's you in control of gastric acid

Product Information

Prescription: 'Tagamet' tablets, PL 0002/0092, each containing 400 mg cimetidine, 56, £16.61. 'Tagamet' tablets, PL 0002/0063, each containing 200 mg cimetidine, 500, £74.15. 'Tagamet' Syrup, PL 0002/0073, containing 200 mg cimetidine per 5 ml, 200 ml, £28.17.

Indications: Duodenal ulcer, benign gastric ulcer, recurrent and stomach ulceration, oesophagogastric reflux disease. Other conditions where reduction of gastric acid is beneficial: prophylaxis of stress-induced gastrointestinal haemorrhage and of acid aspiration (Wendelborg's) syndrome; malabsorption and fluid loss in short bowel syndrome; Zollinger-Ellison syndrome.

Dosage: Usual dosage: Adults: Duodenal ulcer, 400 mg b.d. with breakfast and at bedtime, or 200 mg t.d.s. with meals and 400 mg at bedtime (1.0 g/day) for at least 4 weeks. To prevent relapse, 400 mg at bedtime, 400 mg morning and at bedtime for at least 6 months. Benign gastric ulcer, 200 mg t.d.s. with meals and 400 mg at bedtime (1.0 g/day) for at least 6 weeks. Oesophagogastric reflux disease, 400 mg t.d.s. with meals and 400 mg at bedtime (1.6 g/day) for 4 to 8 weeks. Prophylaxis of stress-induced

gastrointestinal haemorrhage, up to 2 g a day, divided, to maintain intragastric pH above 4. Prophylaxis of acid aspiration syndrome, 400 mg 30-120 mins before induction of general anaesthesia, 400 mg at start of labour then 200 mg 2-hourly as necessary, maximum 1.6 g. Do not use 'Tagamet' syrup. Zollinger-Ellison syndrome, up to 400 mg q.i.d., rarely up to 2 g a day. Recurrent and stomach ulceration and short bowel syndrome, 200 mg t.d.s. and 400 mg at bedtime (1.0 g/day).

N.B. For full dosage instructions see Data Sheet.

Cautions: Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants: phenytoin and theophylline (see Data Sheet). Prolonged treatment: observe patients periodically. Exclude malignancy in gastric ulcer. Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation.

Adverse reactions: Diarrhoea, dizziness, rash, tiredness. Rarely, mild gynaecomastia, reversible liver damage, confusional states (usually in the elderly or very ill), interstitial nephritis, acute pancreatitis.

Legal Category: POM. 21.783

SK&F SMITH KLINE & FRENCH LABORATORIES LIMITED, Welwyn Garden City, Hertfordshire AL7 1EY
© 1983 Smith Kline & French Laboratories Limited

'Tagamet' is a trade mark. TG AD1273

THE NEW BMW SPECIAL EQUIPMENT RANGE. PUT YOUR MIND, NOT JUST YOUR BODY, AT EASE.



Along with all the space, quiet opulence, and creature comforts that you'd expect in a £17,000 car, the BMW above gives you something far more important.

Peace of mind.

The car is the new BMW 728i Special Equipment. Much of the special equipment on board is there to make it a safer business going from A to B. Especially when conditions are going from bad to worse.

When roads are slippery, for example, you'll find the electronic, anti-lock braking system very reassuring.

Known as ABS, the system lets you slam on the brakes in an emergency without fear of launching your car into an uncontrollable skid. Even on a road like an ice rink.

In tests, cars fitted with ABS stopped safely up to 40% quicker than those without.

ABS is a feature that's also shared by the other two cars in the Special Equipment range: the 732i and the 735i.

The 735i actually takes safety a step further. It warns you of slippery conditions in advance.

An on-board computer monitors, among other

things, the temperature outside the car. If it reaches the temperature at which black ice forms, it sounds a warning bell.

All of which is not to say, however, that a BMW Special Equipment 7 Series is just a foul weather friend.

When the sun is out, you can let it in at the touch of a button with the electric sun roof. When it turns humid, the automatic air conditioning in the 735i will keep you cool and relaxed.

And all year round, all three cars provide a sense of financial well being, thanks to the frugality of their advanced, automatic gearbox. It has an overdrive fourth gear that actually makes it more fuel-efficient than a manual.

Prices for the Special Equipment range start at £16,995 for 728i.


Small price to pay for a car that gives you all the comfort traditional luxury cars do.

Plus all the performance, driving pleasure, and advanced equipment that traditional luxury cars do not.




THE ULTIMATE DRIVING MACHINE


THE BMW 7 SERIES SPECIAL EQUIPMENT RANGE. THE 728SE COSTS £16,995. THE 732i COSTS £19,325. THE 735i COSTS £24,670. DOE FUEL CONSUMPTION FIGURES FOR THE 728SE FOUR SPEED AUTOMATIC: URBAN: 19.5 MPG (14.5L/100KM) 56 MPG (3.6L/100KM); 75 MPH. 75 MPH: 28.5 MPG (9.9L/100KM). PRICES CORRECT AT TIME OF GOING TO PRESS. INCLUDES CAR TAX AND VAT BUT NOT DELIVERY OR NUMBER PLATES. INCLUSIVE DELIVERY CHARGE, INCORPORATING BMW EMERGENCY SERVICE AND INITIAL SERVICES £185 + VAT. FOR A BMW 7 SERIES INFORMATION FILE, PLEASE WRITE TO: BMW INFORMATION SERVICE, PO BOX 46, HOUNSLAW, MIDDLESEX OR TELEPHONE 01-897 6665. FOR TAX FREE SALES: 56 PARK LANE, LONDON W1. TELEPHONE 01-629 9277.



WHEN
PARKINSON'S DISEASE
TURNS THE
MORNING SHAVE INTO
A NIGHTMARE

EARLY TREATMENT WITH



HELPS RESTORE  THE THREAD OF LIFE

For abridged product information see overleaf



Merck Sharp & Dohme Limited, Hoddesdon, Hertfordshire, EN11 9BU

3.84 SEM.83 GB.9010.J

SINEMET®

Carbidopa and levodopa, MSD

ABRIDGED PRODUCT INFORMATION

Full prescribing information is available on request and should be consulted before prescribing.

Indications

Parkinson's disease and syndrome.

Dosage and administration

Dosage variable.

Patients not receiving levodopa

Usually 1 tablet of 'Sinemet-Plus' three times a day. Adjust as necessary. Maximum daily dose is 8 tablets. If more levodopa required, substitute 'Sinemet'-275, 1 tablet three or four times a day. If further titration needed, increase 'Sinemet'-275 to maximum 8 tablets a day.

Patients receiving levodopa

Discontinue levodopa at least twelve hours (24 hours for slow-release preparations) before starting 'Sinemet'. Dose of 'Sinemet' approximately 30% of previous daily dosage of levodopa.

Usual starting dose 'Sinemet'-275 1 tablet three or four times a day.

Patients requiring less than 1,500 mg levodopa a day start with 'Sinemet-Plus' 1 tablet three or four times a day. Maximum is 8 tablets a day.

Contra-indications

Narrow-angle glaucoma; known hypersensitivity. Do not use in patients with history of melanoma or with suspicious undiagnosed skin lesions. Discontinue MAO inhibitors at least two weeks before starting 'Sinemet'.

Pregnancy and lactation

Not recommended in lactating mothers. Use in women of childbearing potential requires that anticipated benefits be weighed against possible hazards should pregnancy occur.

Precautions

Not recommended for drug-induced Parkinsonism. Use cautiously in patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic, endocrine disease, psychoses, chronic wide-angle glaucoma, with a history of myocardial infarction; and when receiving antihypertensives (adjust dosage if necessary). Monitor carefully for mental changes, depression with suicidal tendencies, and other serious antisocial behaviour. Observe carefully patients with history of severe involuntary movements or psychoses when 'Sinemet' substituted for levodopa.

GI haemorrhage may occur in patients with history of peptic ulcer. If general anaesthesia is required, 'Sinemet' may be continued whilst patient permitted oral intake. Usual daily dosage may be given when oral medication is possible.

Transient abnormalities in renal function tests, liver function tests, and protein-bound iodine may occur without evidence of disease. Not recommended for children under 18 years of age.

Side effects

Choreiform, dystonic, and other involuntary movements are most common. Other mental changes are less common. Less frequent are cardiovascular irregularities, the 'on-off' phenomenon, GI intolerance, and dizziness.

Rarely, GI bleeding, duodenal ulcer, hypertension, phlebitis, leucopenia, and agranulocytosis. Positive Coombs test reported but haemolytic anaemia extremely rare.

Other side effects include psychiatric, neurological, GI, dermatological, respiratory, urogenital, special senses, hot flushes, weight gain or loss, and abnormalities in laboratory tests.

Basic NBS cost

'Sinemet-Plus' (25 mg carbidopa/100 mg levodopa BP) tablets £13.07 per 100 pack;

'Sinemet'-275 (25 mg carbidopa/250 mg levodopa BP) tablets £14.89 per 100 pack;

'Sinemet'-110 (10 mg carbidopa/100 mg levodopa BP) tablets £27.70 per 100 pack.

Product licence numbers

'Sinemet-Plus', 0028/0180

'Sinemet'-275, 0028/0086

'Sinemet'-110, 0028/0084

® denotes registered trademark


™ denotes trademark

Issued April 1983



Merck Sharp & Dohme Limited
Hoddesdon, Hertfordshire, EN11 9BU

3.84.SEM.83.GB.9010.J



THE ECLIPSE OF TODAY'S **ANTIBIOTICS?**

**AMINO ACID
ANTIBIOTICS**

**CHLORAMPHENICOL
ANTIBIOTIC**

**100 AMINO ACID
ANTIBIOTIC**

**100 AMINO ACID
ANTIBIOTIC**

**AMINO ACID
ANTIBIOTIC**

**PIPERAMIDE
ANTIBIOTIC**

**GLAMAMIDE
ANTIBIOTIC**

**CHLORAMPHENICOL
ANTIBIOTIC**

**CHLORAMPHENICOL
ANTIBIOTIC**

**CHLORAMPHENICOL
ANTIBIOTIC**

ANNOUNCING
A TRULY
REMARKABLE
CEPHALOSPORIN

NEW

FORTUM

ceftazidime

For the first time.
The bactericidal power
of aminoglycosides
and exceptional
antipseudomonal activity
from an extended spectrum
cephalosporin.

Hospital antibiotics created in Britain by

Glaxo

A TRULY REMARKABLE NEW CEPHALOSPORIN

FORTUM ceftazidime

PRESCRIBING INFORMATION

Presentation

Fortum for injection is supplied in vials containing 500mg, 1g and 2g ceftazidime (as pentahydrate) with sodium carbonate.

Uses

Fortum is a bactericidal cephalosporin antibiotic which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative bacteria.

It is indicated for the treatment of single infections and for mixed infections caused by two or more susceptible organisms. Fortum, because of its broad antibacterial spectrum, may be used alone as first choice drug, pending sensitivity test results.

Dosage and administration

The usual adult dosage is in the range 1g to 6g i.m. or i.v. per day (see Data Sheet for details).

Contra-indication

Fortum is contra-indicated in patients with known hypersensitivity to cephalosporin antibiotics.

Precautions

Cephalosporins may, in general, be given safely to patients who are hypersensitive to penicillins. Care is indicated in patients who have experienced an anaphylactic reaction to penicillin.

Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with nephrotoxic drugs. Clinical experience with Fortum has shown that this is not likely to be a problem at the recommended dose levels. Reduce dosage when renal function is impaired (see Data Sheet).

As with all drugs, Fortum should be administered with caution during the early months of pregnancy and in early infancy. Fortum is excreted in human milk in low concentrations.

Fortum does not interfere with enzyme-based tests for glycosuria. Slight interference with copper reduction methods may be observed. Fortum does not interfere in the alkaline picrate assay for creatinine.

Fortum and aminoglycosides should not be mixed in the same giving set or syringe.

As with other broad spectrum antibiotics, prolonged use of Fortum may result in the overgrowth of non-susceptible organisms (e.g., *Candida*, *Enterococci*) which may require interruption of treatment or adoption of appropriate measures.

Side effects

Fortum is generally well tolerated with only infrequent adverse reactions, e.g., pain and/or inflammation after i.m. administration and phlebitis and/or thrombophlebitis after i.v. administration, rashes, fever, pruritis, gastro-intestinal disturbances, headache, dizziness, paraesthesiae and bad taste. Transient changes in laboratory values may occur including: eosinophilia, a positive Coombs' test, thrombocytosis and slight rises in hepatic enzymes.

Basic NHS cost (exclusive of VAT)

The basic NHS cost of Fortum is £9.90 per gram.

Available in packs of: 5 x 500mg, 5 x 1g and 5 x 2g vials and an infusion pack of 5 x 2g vials.

Product Licence numbers

500mg: 0004/0292

1g: 0004/0293

2g: 0004/0294

Further information is available on request from:

Glaxo

Glaxo Laboratories Limited, Greenford, Middlesex UB6 0HE

Fortum is a Glaxo trade mark.

Hospital antibiotics created in Britain by

Glaxo



NEW DRUGS

In the past few years the number of important new drugs and our understanding of pharmacology have continued to increase. Reliable and unbiased information on the therapeutic use of these agents is, however, not always readily available. Articles recently published in the *BMJ* on entirely new groups of drugs – H₂ receptor antagonists, calcium antagonists, captopril – and on new members of groups of drugs already available – beta-blockers, tranquillisers, hypnotics, diuretics – fill this gap and are now collected together in book form. Busy practitioners will find that this comprehensive review allows them to make a more rational choice of treatment.

Price: Inland £6.50; Overseas £7.50/USA\$13.00
(Inland £6.00; Overseas £7.00/USA\$12.00
to BMA members)


Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal
BMA House, Tavistock Square, London WC1H 9JR
or any leading bookseller

NEW DRUGS




Aim at the most likely cause of skin infections.

The most likely cause of skin infections in hospital is *Staphylococcus aureus*.¹ Unfortunately this organism is now usually resistant to many widely used antibiotics such as penicillin V and G, ampicillin and amoxycillin.²

It is therefore important, in the treatment of these infections, to choose an antibiotic upon which you can depend to eradicate *Staphylococcus aureus*.

Floxapen is active against 98% of isolates of *Staphylococcus aureus*²; you can rely on it for effective treatment.

Make Floxapen your first choice for skin infections.



Floxapen

flucloxacillin
accurate against Staph.

References 1. J. Hosp. Inf. 1981, 2 (Suppl.), 35-39.
2. Audit of Antibiotic Sensitivity Reports 1981, Market
Investigations (P & A) plc.

PRESCRIBING INFORMATION **Uses** Floxapen is a penicillinase-stable penicillin, indicated for the treatment of infections due to Gram-positive organisms, including infections caused by penicillinase-producing staphylococci. **Dosage** **ADULTS:** ORAL 250mg q.i.d. IM = 250mg q.i.d. IV = 250-500mg q.i.d. CHILDREN 2-10 years: 1/2 adult dose. Under 2 years: 1/4 adult dose. Systemic dosages may be doubled where necessary. **Administration** **ORAL:** Oral doses should be administered 1/2-1 hour before meals. Floxapen syrup may be diluted with syrup B.P. INTRAMUSCULAR: Add 1.5 ml Water for Injections B.P. to 250mg vial contents or 2ml Water for Injections B.P. to 500mg vial contents. INTRAVENOUS: Dissolve 250-500mg in 5-10ml Water for Injections B.P. or 1g in 15-20ml Water for Injections B.P. Administer by slow intravenous injection (three to four minutes). Floxapen may also be added to infusion fluids or injected, suitably diluted, into the drip tube over a period of three to four minutes. For information on dosage and administration of Floxapen by Intrapleural, Intra-articular and Intrathecal injection or by Nebuliser solution please refer to the Data sheet or Package Enclosure Leaflet. **Contra-Indications** Penicillin hypersensitivity, ocular administration. **Side-effects** As with other penicillins.

Availability and basic NHS prices
(Correct at October 1983)
Favourable Hospital Rates are available from the Company

CAPSULES
250mg-£4.32 for 20,
500mg-£8.64 for 20.

SYRUP
125mg/5ml-£3.42 per 100ml.

VIALS FOR INJECTION
1g-£3.83 each.
500mg-£1.91 each.
250mg-96p each.




Further information is available on request to the Company.
Floxapen (flucloxacillin) is a product of British research from
Beecham Research Laboratories
Brentford, Middlesex TW8 9BD



Floxapen and the BRL logo are trademarks


PL 0038/5051 5052 5053 5055 5056 5058 BRL/R3058



24
HOUR
control¹



WELL
TOLERATED²



abridged Product Information
Full prescribing information is available on request and should be consulted before prescribing.
Indication Mild to moderate hypertension. **Dosage** One to two tablets 1 day. **Contra-Indications** Bronchospasm, bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second- and third-degree AV block, congestive heart failure, right ventricular failure, significant cardiomegaly, cardiogenic shock. Hyperkalaemia. Ururia, renal insufficiency, severe or progressive renal disease. Anesthetics causing myocardial depression, hypersensitivity to components, or to sulphonamide-derived drugs. Potassium-conserving agents or supplements (except in severe and/or

refractory cases of hypokalaemia). **Pregnancy and lactation** Not recommended. **Precautions** Abrupt withdrawal is not recommended. **Congestive cardiac failure:** caution in cardiomegaly or history of cardiac failure. **Cardiac arrhythmias:** if risk of heart failure, monitor for bradycardia, AV block and respiratory distress. Withdraw if cardiac failure persists. **Surgery:** in patients with angina, withdraw prior to elective surgery. **Renal and hepatic disease:** caution in renal or hepatic disease. Hypokalaemia or hyperkalaemia may occur. **Diabetes mellitus, hypoglycaemia:** caution in hypoglycaemics and diabetics, and determine renal function. Discontinue three days before glucose tolerance testing. Reports of skin rashes and dry eyes associated with beta-blockers. Incidence is small; most cases symptoms have cleared

on withdrawal. Gradual withdrawal should be considered. Sensitivity reactions may occur. Thiazides may exacerbate or activate SLE reactions. Beta-blockers may mask hyperthyroidism. Hypercalcaemia and hypophosphataemia reported with thiazides. Discontinue prior to testing for parathyroid function. Hyperuricaemia or acute gout precipitated. Not recommended for children. **Side effects** Asthenia and bradycardia are common. GI intolerance. A few reports of GI bleeding and activation of probable pre-existing peptic ulcer associated with amiloride. **Other:** rash, pruritus, visual and psychiatric disturbances. Leucopenia, agranulocytosis, thrombocytopenia, aplastic anaemia and haemolytic anaemia rarely. Purpura urticaria, photosensitivity, necrotising angiitis, fever, respiratory distress,

MODUCREN

Hydrochlorothiazide, amiloride hydrochloride, and timolol maleate

Long-term control³

reliably controls
blood pressure
with the minimum
of fuss

pneumonitis, anaphylactic reactions, abnormal liver function test, and hyperuricaemia reported. Thiazides commonly cause headache, restlessness, jaundice, pancreatitis, xanthopsia, hyperglycaemia, glycosuria, and hyperuricaemia. Diuresis may induce dry mouth, thirst, paraesthesiae, saladenitis, dizziness, vertigo, muscle spasm, and orthostatic hypotension. One patient developed complete heart block with amiloride. *Timolol maleate related to beta-blockade:* GI intolerance, dizziness, headache, and dyspnoea. Less commonly insomnia, dreams, nightmares, congestive heart failure, severe bradycardia, bronchospasm, AV block, hypotension, cold extremities, Raynaud's phenomenon, fatigue, sedation, and mental depression. Hallucinations rare. Rashes and pruritis occasionally, and one

case of exfoliative dermatitis. Basic NHS cost 'Moducren' (25 mg hydrochlorothiazide, 2.5 mg amiloride hydrochloride, and 10 mg timolol maleate) Tablets, £6.96 per 28 calendar pack.

Product licence number 0025/0141.

• denotes registered trademark.

References

1. Hornung, R. S., et al. *Brit. J. clin. Pharmacol.*, 1982, 14, 415.
2. Cooper, W. D., et al. *Brit. J. clin. Pract.*, 1983, 37 (3), 99.
3. Pittaway, D. S. *Afr. med. J.*, 1980, 58, 231.

MODUCREN



Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

PAIN

responds  rapidly to

new **brufen** **600**

Ibuprofen B.P.

fast, dependable relief of

post-operative pain
post-episiotomy pain
dental pain
dysmenorrhoea
non-articular rheumatism
soft-tissue injuries

Prescribing Information. **Presentation:** Light-magenta, film-coated tablets containing 600mg of Ibuprofen B.P. **Uses:** Rheumatoid arthritis (including Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid arthropathies. Non-articular rheumatic conditions such as capsulitis, bursitis, tendinitis, tenosynovitis, low back pain, soft tissue injuries. As an analgesic in mild to moderate pain. **Dosage:** Adult: Brufen 600 is indicated three times daily (1800mg/day) for acute conditions. Total daily dose should not exceed 4000mg. **Contra-indications:** Severe or active peptic ulceration. **Warnings:** Prescribe with caution in patients with asthma and those who have developed bronchospasm with other non-steroidal agents. Avoid, if possible, during pregnancy. **Side-effects:** Dyspepsia, gastrointestinal intolerance and bleeding; skin rashes. Less frequently, thrombocytopenia; rarely toxic amblyopia. **Basic N.H.S. Price:** Brufen 600 100 pack £8.55. **Product Licence No:** Brufen 600 PL0014/0264. Brufen is a registered Trademark.



The Boots Company PLC Nottingham
Further information on Brufen 600 is available on request.

just one tablet three times daily

Presentation Vials containing 500mg, 1g or 2g of cefotaxime sodium. **Indications** Infections before identification of the organism. Infections caused by bacteria of established sensitivity, including chest infections, septicema, urinary tract infections, soft tissue infections, obstetric and gynaecological infections, bone and joint infections, meningitis, gonorrhoea. **Dosage** Claforan is administered i.m. or i.v. Moderate infections: 1g 12-hourly. Severe infections: up to 1g daily in 3 or 4 divided doses. For infections caused by sensitive *Pseudomonas* spp., doses of more than 8g daily are usually required. Children: 100-150mg/kg/day in 2 to 4 divided doses. Up to 200mg/kg/day may be given in very severe infections. **Contra-indications**: Moderate infections: 50mg/kg body weight daily in 2 to 4 equally divided doses. In cases of severe infection, divided daily doses of 150-200mg/kg have been given. **Dosage in renal impairment**: Reduced dosage is only required in severe renal failure (GFR<5ml/min) when, after an initial loading dose of 1g, the daily dose is halved without change in frequency of dosing. **Contra-indications**: Known allergy to cephalosporins. **Precautions**: Cephalosporin antibiotics may usually be given safely to patients who are hypersensitive to penicillins. Special care is indicated in patients who have had an anaphylactic reaction to penicillins. Patients with severe renal dysfunction - see previous. Cephalosporin antibiotics at high dosage should be given with caution to patients receiving aminoglycoside antibiotics or potent diuretics such as furosemide. At recommended doses, enhancement of nephrotoxicity is unlikely. A false-positive reaction to glucose in the urine with aminoglycoside antibiotics. The safety of Claforan in human pregnancy has not been established. **Side effects**: Adverse reactions are rare and generally mild and transient, but include diarrhoea, candidiasis, aches, fever, eosinophilia, leucopenia, transient rises in liver transaminase and alkaline phosphatase, transient pain at the site of injection and phlebitis. **Product licence number** 0109/0074. **Package quantities and basic N.H.S. price** Vials of 500mg, 1g and 2g in packs of 10. One gram vial £4.95. **Date of preparation** May 1983. **Further information available from** Roussel Laboratories Ltd., Roussel House, Wembley, Middlesex HA9 0NF.



When faced with serious bacterial infection, you can have confidence in Claforan's unsurpassed spectrum to cover gram positive and gram negative organisms, including many anaerobes.


Excellent safety profile

Wide clinical experience has established an excellent safety profile for Claforan, so you're unlikely to see side effects such as renal toxicity, gastric bleeding or adverse drug interactions which you may observe with some other injectable antibiotics.

Claforan cefotaxime

The first step to take in moderate to serious infection

What's new about



New 2ml i.m./i.v. presentation

Zantac Injection is now available in a 2ml presentation, enabling administration as an i.m. 50mg/2ml injection, as a slow (over 1 minute) i.v. injection of 50mg/2ml, and as an i.v. infusion at 25mg per hour for 2 hours.

Doses may be repeated every 6-8 hours.

New indications


Zantac Injection is now indicated in the following conditions where reduction of gastric secretion and acid output is desirable:

- the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients.
- the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers.
- the prophylaxis of acid aspiration particularly in obstetric patients during labour. (Mendelson's syndrome).

Simply right in H₂ parenteral therapy

Prescribing Information: DOSAGE AND ADMINISTRATION: ADULTS: ZANTAC INJECTION MAY BE GIVEN EITHER AS AN INTRAMUSCULAR INJECTION, A SLOW (OVER ONE MINUTE) INTRAVENOUS INJECTION OF 50mg, WHICH MAY BE REPEATED EVERY SIX TO EIGHT HOURS; OR AS AN INTRAVENOUS INFUSION AT A RATE OF 25mg PER HOUR FOR TWO HOURS. THE INFUSION MAY BE REPEATED AT SIX TO EIGHT HOUR INTERVALS. SIDE EFFECTS: NO SERIOUS ADVERSE EFFECTS HAVE BEEN CONFIRMED TO DATE IN PATIENTS TREATED WITH ZANTAC INJECTION. PRECAUTIONS: WHERE GASTRIC ULCER IS SUSPECTED, THE POSSIBILITY OF MALIGNANCY SHOULD BE EXCLUDED BEFORE THERAPY WITH ZANTAC IS INSTITUTED. IN THE PRESENCE OF SEVERE RENAL IMPAIRMENT IT IS RECOMMENDED THAT ZANTAC BE ADMINISTERED IN DOSES OF 25mg. LIKE OTHER DRUGS, ZANTAC SHOULD NOT BE USED IN PATIENTS WITH A HISTORY OF ANAPHYLACTIC REACTIONS. CONTRAINDICATIONS: ZANTAC INJECTION HAS BEEN SHOWN TO BE COMPATIBLE WITH THE

Zantac Injection?



Minimises the risk of drug interaction

Zantac does not block the action of the liver enzyme system^{1,2} responsible for the breakdown of theophylline, some commonly used benzodiazepines or anaesthetics. This may be particularly important for patients such as those in intensive care who require sedation.

Similarly this would apply to patients in whom a general anaesthetic is needed for further investigation, elective surgery or obstetrics.



2ml Zantac i.m./i.v. Injection

I.M./I.V. INJECTION
Zantac
RANITIDINE

FOLLOWING INTRAVENOUS INFUSION FLUIDS: 0.9% SODIUM CHLORIDE BP, 5% DEXTROSE BP, 0.18% SODIUM CHLORIDE AND 4% DEXTROSE BP, 4.2% SODIUM BICARBONATE BP AND HARTMANN'S SOLUTION. ALL UNUSED ADMIXTURES OF ZANTAC INJECTION WITH INFUSION FLUIDS SHOULD BE DISCARDED 24 HOURS AFTER PREPARATION. STORE IN A COOL PLACE. PROTECT FROM LIGHT. BASIC NHS COST (EXCLUSIVE OF VAT): 5 x 50mg £3.21. PRODUCT LICENCE NUMBER: 4/0289.

FURTHER INFORMATION ON ZANTAC (TRADE MARK) IS AVAILABLE FROM GLAXO LABORATORIES LTD, GREENFORD, MIDDX. UB6 0HE.

REFERENCES: 1. DATA ON FILE, GLAXO GROUP RESEARCH, 2. HENRY, D.A. ET AL; BR. MED.J., 1980, 2, 775-777.

Glaxo

ALCOHOL PROBLEMS

In recent years alcohol problems have increased dramatically and the thinking on them has undergone a revolution. *Alcohol Problems* brings together two series of articles published in the *BMJ*—the ABC of Alcohol, with its emphasis on straightforward advice for the clinician, and *Alcohol and Alcoholism*, Dr Richard Smith's more discursive survey of current thinking and controversies. Together they cover both the clinical aspects of managing alcohol problems and the social and political factors that surround them.


Price: Inland £5.50
Overseas £8.00/USA\$14.00
(Inland £5.00;
Overseas £7.50/USA\$13.00
to BMA members)

Despatched by air overseas

Payment must be enclosed with order


Order your copy now

From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



“... a good account of the right kinds of observations to make in order to detect people with alcohol problems... These articles are succinct and well written and provide the best source of information and reference for general practitioners and trainees. This is an outstanding series which will be of great value to everyone concerned with the prevention, identification and management of alcohol-related problems.”

Update 1983; 26: 301



Prescribing information

Dosage

Adults: Generally 750mg t.d.s. i.m. or i.v. Severe infections 1.5 grams t.d.s. i.v. Frequency of injections can be increased to six-hourly if necessary.

Infants and children: 30 to 100mg/kg/day in three or four divided doses. 60mg/kg/day will be appropriate for most infections.

Neonates: 30 to 100mg/kg/day in two or three divided doses.

Gonorrhoea: Single dose of 1.5 grams (2 x 750mg into different sites).

Prophylaxis: The usual dose of 1.5 grams i.v. with induction of anaesthesia for abdominal, pelvic and orthopaedic operations, may be supplemented with two 750mg i.m. doses eight and sixteen hours later. In cardiac, pulmonary, oesophageal and vascular operations, the usual dose is 1.5 grams i.v. with induction of anaesthesia continuing with 750mg i.m. t.d.s. for a further 24 to 48 hours. In total joint replacement, 1.5 grams cefuroxime powder may be mixed dry with each pack of methyl methacrylate cement monomer before adding the liquid polymer.

Contra-indications

Hypersensitivity to cephalosporins.

Precautions

Cephalosporins may, in general, be given safely to patients who are hypersensitive to penicillins. Care is indicated in patients who have experienced an anaphylactic reaction to penicillin. As with all drugs, Zinacef should be administered with caution during the early months of pregnancy. Zinacef does not interfere with enzyme-based tests for glycosuria. Slight interference with copper reduction methods may be observed. Zinacef may cause false-negative results in the ferricyanide test for glucose. This antibiotic does not interfere in the alkaline picrate assay for creatinine. Zinacef should not be mixed in the syringe with aminoglycoside antibiotics. Reduce dosage when renal function is markedly impaired.

Cephalosporins at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as furosemide, as these combinations are suspected of adversely affecting renal function. Clinical experience with Zinacef has shown that this is not likely to be a problem at the recommended dose levels.

Side effects

Adverse reactions are rare and generally mild and transient, e.g. rashes, gastro-intestinal disturbances, decreased haemoglobin concentration, eosinophilia, a positive Coombs' test, transient rises in serum liver enzymes and transient pain (after i.m. injection). As with other antibiotics, prolonged use may result in the overgrowth of non-susceptible organisms, e.g. *Candida*.

Product Licence number:
4/0263

Recommended price:
(exclusive of VAT)
5 x 250mg £4.90
5 x 750mg £14.70
1.5 gram £5.88
1.5 gram £5.88
infusion pack

Further information on Zinacef (trade mark) is available from:

Glaxo

Glaxo Laboratories Limited
Greenford, Middlesex UB6 0HE

PROPHYLACTIC ZINACEF

injectable cefuroxime

PROTECTION FROM WITHIN

NOCTAMID'S HYPNOTIC DURATION IS CLOSE TO IDEAL



Very short-acting hypnotics
cannot ensure a full night's sleep and may cause rebound anxiety¹.

Noctamid. 6-8 hours
normal sleep² without impaired daytime performance.³

Long-acting hypnotics
can impair performance the following day⁴ and tend to accumulate in the body.¹

NOCTAMID 1mg NOCTE

lormetazepam

FAST ASLEEP ALL NIGHT-WIDE AWAKE ALL DAY

Abbreviated Prescribing Information. **Presentation:** Tablets containing 1mg and 0.5mg lormetazepam. **Indication:** Short-term treatment of insomnia. **Dosage:** Adults: 1mg. Elderly patients: 0.5mg. **Contra-indications:** Known sensitivity to benzodiazepines. Myasthenia gravis. **Precautions:** Noctamid, other centrally-acting drugs and alcohol enhance each other's actions. Users should beware of dizziness or drowsiness when driving or operating machinery. Use during pregnancy is not recommended. Prolonged high dosage may occasionally cause psychological dependence. **Possible side effects:** Include headaches, nausea, drowsiness, blurring of vision, dizziness and ataxia. More severe psychological and physical side-effects have been known to occur rarely with some benzodiazepines, but have not been reported with Noctamid. **Legal category:** POM. **Product licence no.** 0.5mg 0053/0117. 1mg 0053/0118. **Product licence holder:** Schering Chemicals Limited, The Brow, Burgess Hill, West Sussex RH15 9NE. **Basic NHS price:** 1mg/30 tablets: £2.23. 1mg/100 tablets: £7.44. 0.5mg/30 tablets: £1.62. 0.5mg/100 tablets: £5.40. **References:** 1. Oswald I. Psychiatry in Practice 1982; 1 (12): 8-13. 2. Jovanovic U J et al. Waking and Sleeping 1980; 4: 223-225. 3. Heidrich H et al. Int J Clin Pharmacol Ther Toxicol

Shering

Humulin

Human Insulin (crb)

'HUMULIN'S ▼ 'HUMULIN'I ▼ 'HUMULIN' Zn ▼
Human insulin (crb) **Presentation:** Humulin S: A sterile, aqueous solution of human insulin (crb), 40, 80 and 100 IU/ml. Humulin I: A sterile suspension of isophane human insulin (crb), 40, 80 and 100 IU/ml. Humulin Zn: A sterile suspension of crystalline human insulin (crb), 100 IU/ml. **Uses:** For the treatment of insulin-dependent diabetics. **Dosage and Administration:** The dosage should be determined by the physician, according to the requirements of the patient. Humulin S may be administered by subcutaneous, intramuscular or intravenous injection. Humulin I and Humulin Zn should be administered by subcutaneous or intramuscular injection only. Humulin S may be administered in combination with Humulin I or Humulin Zn as required. Humulin I and Zn: Rotate vial in palm of hands before use to re-suspend. **Mixing of insulins:** The shorter-acting insulin should be drawn into the syringe first, to prevent contamination of the vial by the longer-acting preparation. It is advisable to inject immediately after mixing. **Contra-indications, Warnings, etc. Contra-indications:** Hypoglycaemia. Under no circumstances should Humulin I or Humulin Zn be given intravenously. **Precautions: Usage in pregnancy:** Insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Transferring from other insulins:** A small number of patients transferring from insulins of animal origin may require a reduced dosage, especially if they are very tightly controlled and bordering on hypoglycaemia. The risk of hypoglycaemia can be considered minimal if the daily dosage is less than 40 IU. Insulin-resistant patients receiving more than 100 IU daily should be referred to hospital for transfer. **Side effects:** Lipodystrophy, insulin resistance and hypersensitivity have rarely been reported. **Legal Category:** P **Package Quantities:** 10ml glass vials in packs of 5. **Price:** Humulin S: 40 IU/ml £2.70, 80 IU/ml £5.40, 100 IU/ml £6.44. Humulin I: 40 IU/ml £2.70, 80 IU/ml £5.40, 100 IU/ml £6.44. Humulin Zn: 100 IU/ml £6.44.

Product Licence Numbers:

Humulin S 40 IU/ml 0006/0163
Humulin S 80 IU/ml 0006/0164
Humulin S 100 IU/ml 0006/0165
Humulin I 40 IU/ml 0006/0166
Humulin I 80 IU/ml 0006/0167
Humulin I 100 IU/ml 0006/0168
Humulin Zn 100 IU/ml 0006/0179.

Date of preparation: December 1983. **Full Prescribing Information Available From:** Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire, RG21 2XA. Or from: Eli Lilly and Company Limited, 5 Percy Place, Dublin 4. Telephone: 680 179. 'HUMULIN' is a trade mark. HU69 Dec '83

1. Johnson I.S., Diabetes Care 1982, Vol. 5, Suppl. 2, 4-12. 2. Fineberg, S.E. et al (Indianapolis), Diabetes May 1983, 32, Suppl. 1, 3A.



PROCEDURES IN PRACTICE

An illustrated step-by-step guide for doctors making their first attempts at the procedures commonly used in hospital practice. The articles explain the techniques in detail and give indications and contraindications for a range of tasks from setting up a drip to aspirating bone marrow.

Price: Inland £4.50
Overseas £7.00/USA\$13.00
(Inland £4.00; Overseas £6.50/USA\$12.00
to BMA members)

Despatched by air overseas


Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal, BMA House,
Tavistock Square, London WC1H 9JR
or any leading bookseller

PROCEDURES IN PRACTICE

ARTICLES FROM THE BRITISH MEDICAL JOURNAL



LETTERS TO A YOUNG DOCTOR

PHILIP RHODES


Faced with increasing competition and even the prospect of unemployment young doctors need sound advice on how they should plan their careers. This series of articles by Professor Philip Rhodes, begins with advice to preregistration house officers and then considers the choice open to them after registration. There are sections on study leave, applying for jobs, and interviews, and chapters giving special advice to women and overseas doctors. Examinations, research, teaching, administration, and postgraduate education are also covered.

Price: Inland £6.00
Overseas £8.00/USA\$14.00
(Inland £5.50;
Overseas £7.50/USA\$13.00
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



GASTRI


BOTTLE



New Motilium Suspension

Trademark
(domperidone)

the first specific peripheral anti-nauseant/anti-emetic
-for a well composed stomach



MOTILIUM® Prescribing Information Presentation: White tablets containing domperidone maleate equivalent to 10mg domperidone base. Sweet tasting, white suspension containing domperidone 1mg/ml. 2ml colourless ampoules each containing 5mg/ml domperidone. **Uses:** Adults: acute nausea and vomiting from any cause. Children: nausea and vomiting following cancer chemotherapy or irradiation only. **Dosage:** Adults: 10-20mg by mouth or 1-2 ampoules by IM or IV injection at 4-8 hourly intervals. Patients requiring intravenous MOTILIUM® who are also receiving concomitant cytotoxic chemotherapy or who are predisposed to hypokalaemia or cardiac arrhythmias should receive an infusion diluted 1:10 with saline over 15-30 minutes. **Contra-indications, Warnings etc:** No specific contra-indications. MOTILIUM® produces a rise in serum prolactin, however the clinical relevance of this has not yet been established. Although no teratogenic effects have been observed in animals, the safety of MOTILIUM® in pregnancy has not yet been established. **Product Licence Numbers:** Tablets 0242/0071, Injection 0242/0077, Suspension 0242/0077. **Basic NHS Cost:** 9p per 10mg tablet (ex 250 pack). Pack of 10 ampoules: £3.10. Bottle of 200ml suspension: £1.80 (Correct at time of printing). Further information is available from: **Janssen Pharmaceutical Limited**, Grove, Wantage, Oxon. OX12 0DQ. *Trademark © JPL/154/83

Wellcome introduces CEFIZOX

ceftizoxime sodium



except

Prescribing information:

Presentation: Vials containing 500mg, 1g and 2g of ceftizoxime as the sterile sodium salt.


Uses: Broad-spectrum, bactericidal, cephalosporin antibiotic. Indications include lower respiratory tract infections, genito-urinary tract infections including gonorrhoea, intra-abdominal infections, septicaemia, skin and soft tissue infections. Cefizox is active against a wide range of Gram-positive and Gram-negative organisms and is stable to a broad spectrum of beta-lactamases produced by both aerobic and anaerobic organisms.

Dosage and administration: By slow intravenous injection,

by continuous or intermittent intravenous infusion, or by deep intramuscular injection. For reconstitution details see Data Sheet. Modification of the following guideline dosages is necessary in patients with impaired renal function (see Data Sheet). **Adults:** urinary tract infection, 0.5-1g 12-hourly, IM or IV; gonorrhoea, 1g single dose, IM; other infections, 1-2g 8-12 hourly, IM or IV; severe or life-threatening infections, 2-3g 8-hourly, IM or IV. **Children over the age of 3 months:** 30-60 mg/kg bodyweight/day in 2-4 divided doses, increased in severe or life-threatening infections to 100-150mg/kg body-weight/day. The total dose should not exceed the adult dose. **Under the age of 3 months:** insufficient data to recommend use.

Contra-indications: Hypersensitivity to cephalosporin antibiotics.

Precautions: Renal status should be monitored, especially in seriously ill patients receiving maximum dose therapy and co-administration of aminoglycoside antibiotics. Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. As with any other antibiotic, prolonged use may result in overgrowth of non-susceptible organisms. Caution in penicillin-sensitive patients because of possible cross-reaction. **Side- and adverse effects:** Cefizox is generally well



The excellent *in vivo* performance of Cefizox is the sum of many factors. Most notably, its powerful spectrum of antibacterial activity, stability to β -lactamases, and highly effective tissue penetration.

Potent antibacterial spectrum

Cefizox is a powerful, third-generation, injectable cephalosporin. It has a wide spectrum of activity against both Gram-negative and Gram-positive aerobic and anaerobic organisms including *E. coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *H. influenzae*, *Strep. pneumoniae*, *Staph. aureus* and *Strep. pyogenes*.^{1,2}

It is also active against hospital opportunist pathogens not so frequently encountered, such as indole-positive *Proteus*, *Serratia marcescens*, *Morganella morganii*, and *Enterobacter*.^{1,2}

Superior β -lactamase stability

Cefizox has excellent β -lactamase stability, and is resistant to a wider range of β -lactamases than cefotaxime.³

Excellent tissue penetration

After a single dose, concentrations of Cefizox in most tissues and body fluids are easily in excess of the MIC of likely pathogens.

Study has shown that Cefizox achieves greater concentration in most tissues and body fluids than cefotaxime, after equivalent doses.⁴

And, unlike cefotaxime, Cefizox is not metabolised.⁵ Thus the full therapeutic effect of Cefizox is maintained.

International clinical success

Extensive experience confirms that Cefizox provides excellent clinical results against opportunist hospital pathogens.

It has been shown to be highly effective in lower respiratory tract infections, genito-urinary tract infections including gonorrhoea, intra-abdominal infections, septicaemia, and skin and soft tissue infections.²

Cefizox has also been notably successful in treating infections resistant to ampicillin, carbenicillin, cefamandole, tobramycin or gentamicin.⁶

And Cefizox has proved suitable for use in neutropenic patients⁷ and children.⁸

With a broad spectrum of antibacterial activity, proven efficacy and a low level of side effects,⁹ Cefizox is a logical choice in serious infection. Especially before the infecting organism is identified, where multiple infection is suspected, or the infection is resistant to other cephalosporins, aminoglycosides or penicillins.

When infection threatens, Cefizox is an excellent choice.

CEFIZOX

ceftizoxime sodium

References 1 Barry, A.L. *et al* (1982), *J. Antimicrob. Chemother.*, **10**, Suppl. C, 25. 2 Parks, D. *et al* (1982), *ibid.*, 327. 3 Simpson, I.N. *et al* (1982), *J. Antimicrob. Chemother.*, **9**, 357. 4 Gerding, D.N. and Peterson, L.R. (1982), *J. Antimicrob. Chemother.*, **10**, Suppl. C, 105. 5 Quintiliani, R. and Nightingale, C.H. (1982), *ibid.*, 99. 6 Neu, H.C. (1982), *ibid.*, 193. 7 Lawson, R.D. and Baskin, R.C. (1982), *ibid.*, 159. 8 Shikuma, C.M. *et al* (1982), *ibid.*, 293. 9 Platt, R. (1982), *ibid.* 135.

Cefizox is a Trade Mark.

tolerated. The most common adverse reactions have been local following IM or IV injection. These include burning, cellulitis, pain, induration, tenderness, paraesthesia and phlebitis. Other adverse reactions include hypersensitivity reactions (rash, pruritis, fever), gastrointestinal disturbance (diarrhoea, nausea, and vomiting), vaginitis, transient eosinophilia, thrombocytosis. Neutropenia, leucopenia and thrombocytopenia have been reported rarely. Some individuals have developed a positive Coombs' test. Transient elevation in SGOT, SGPT, alkaline phosphatase, BUN and serum creatinine have occasionally been observed.

Use in pregnancy and lactation: There are no data in

pregnant women, thus the benefit of using Cefizox in pregnancy should be weighed against the possible hazard. Caution should be exercised if Cefizox is administered to a nursing mother.

Basic NHS costs:

| | |
|---------------------------|--------|
| 1 x 500mg vial (PL3/0174) | £2.76 |
| 1 x 1g vial (PL3/0175) | £5.50 |
| 1 x 2g vial (PL3/0175) | £11.00 |

Further information is available on request.

Wellcome Medical Division
The Wellcome Foundation Ltd, Crewe, Cheshire

Made by Fujisawa Pharmaceutical Co Ltd, Osaka, Japan, for The Wellcome Foundation Ltd, London.



Wellcome



Fujisawa

NEW FROM HEINEMANN MEDICAL

MULTIPLE SCLEROSIS: Psychological and Social Aspects


Edited by Aart F. Simons

This important international book on the psychological and social aspects of multiple sclerosis has been prepared as a resource for all those working in the field of MS care or who study in this area, and for those people with MS who wish to read beyond the pamphlets handed out to them on diagnosis.

The topics discussed include communicating the diagnosis, support of the patient and the family, the emotional disturbance that may accompany MS, and ways in which some of the limitations imposed by the condition may be overcome. With authoritative contributions from both doctors and patients, this book contains a wealth of information and opinion on psychosocial reactions to the disease and the bearing they may have on its outcome.

1984, 142pp, Cased

£3.95



YOUR CHILD WITH ECZEMA: A Guide for Parents

David Atherton, MRCP

Written by a paediatric dermatologist, this is a helpful and sympathetic account for parents of the commonest and most troublesome of childhood skin conditions. It deals with all the questions the parent of eczematous child is likely to ask, making it easier for you to obtain the help and cooperation of the parents in managing a child with eczema.

1984, 192pp, Limp

£4.95

Order now from your bookseller or from the publisher at this address.



William Heinemann Medical Books Ltd
23 Bedford Square, London WC1B 3HH. Tel. No. 01-637 3311.

RARE & UNUSUAL COLLECTIBLES

The Heritage Collection offers discerning collectors the opportunity to acquire a wide range of *rare and beautiful items*—many specially commissioned and unobtainable elsewhere.

Unique and unusual objets d'art, the finest commemorative porcelain, limited edition clocks and precision chronometers, curios and fantasies in precious metals—every single item is carefully selected for its exceptional quality, outstanding value, and unequivocal good taste.

That's why The Heritage Collection has an *international reputation* as a leading supplier of fine art collectibles, and the continuing confidence of satisfied clients from Scotland to Saudi Arabia.

Find out more about us today: we're confident you won't be disappointed. Send £1 for a comprehensive colour catalogue to New Client Services, Dept BMJ, The Heritage Collection, FREEPOST, Newton Abbot, Devon TQ124XA



ABC OF BRAIN STEM DEATH

CHRISTOPHER PALLIS

The subject of brain stem death still arouses misconceptions—witness the response to the BBC *Panorama* programme on transplantation and brain death. Dr Christopher Pallis has dispelled some of the misconceptions, examined the concepts underlying our ideas of death, and described the practical aspects of diagnosing brain stem death. These articles have been collected into a book together with additional material on the wider aspects of the subject, including some of the neurological controversies.

Price: Inland £6.00;
Overseas £7.50/USA\$13.00
(Inland £5.50; Overseas £7.00/USA\$12.00
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal, BMA House,
Tavistock Square, London WC1H 9JR
or any leading bookseller

THE BRIDGEGATE COLLECTION

CHESTERFIELD

| | | |
|-----|------------------------------------|---------|
| 82Y | Mercedes 380 SEC Ivory, all extras | £24,950 |
| 83Y | BMW 520iA Opal, 6,000 miles | £9,450 |
| 84A | BMW 728iA White, Big saving at | £15,950 |
| 81W | BMW 316 auto Reseda, Big Saving at | £4,950 |
| 83Y | BMW 320i, Henna, sun-roof | £8,950 |
| 81X | Ford Escort XR3 Silver | £4,950 |
| 82X | Audi Quattro, red, L.H.D. | £9,950 |
| 83Y | BMW 316, Henna, 5-speed sun-roof | £7,950 |
| 82X | Vauxhall Viceroy Maroon | £4,450 |

Bridgegate Limited
Pottery Lane,
Chesterfield S41 9BN
Tel: Chesterfield 208681



DERBY

| | | |
|-----|-------------------------------------|---------|
| 84A | BMW 525iA, Opal, MSR | P.O.A. |
| 82X | BMW 528i, Sapphire, 6,000 miles | £12,750 |
| 82X | BMW 528iA, Arctic, E/S/R TRX | £10,950 |
| 83Y | BMW 316, Dark Blue, 11,000 miles | £6,250 |
| 83Y | BMW 320i, New model Opal | £8,950 |
| 82Y | BMW 320, Opal, PAS sun-roof | £7,550 |
| 84A | BMW 316 (83 model) Agate, sun roof | £7,995 |
| 82X | BMW 732i, auto, Opal, black leather | £11,950 |
| 81W | BMW 735i, auto, Metallic Green, | £10,450 |

Bridgegate Limited
2 King Street,
Derby DE1 3DB
Tel: Derby 369511



today
and tomorrow

Exirel. The selective bronchodilator which relieves the strain on the right heart.^{1,2}

pirbuterol
No matter how effective previous treatment may have been, asthmatics and bronchitics could still progress towards chronic respiratory disease.

Now, even with today's modern management these patients may have a brighter future.

First and foremost, Exirel provides the immediate and sustained relief of bronchospasm asthmatics need. In comparative studies Exirel has also proved to be as effective

as salbutamol,³ and in animal studies has proved to be more selective than salbutamol.⁴ A further benefit of Exirel was seen in patients with disease progression. Recent studies have shown that Exirel reduces the strain on the right heart.^{1,2}

Exirel.

For today's patient and tomorrow's.

CHRONIC

pirbuterol

* Trade Mar

Prescribing Information. Presentation Exirel metered dose aerosol containing at least 200 inhalations, each activation delivering 0.2mg of pirbuterol as the acetate. Exirel capsules containing 1.0mg or 1.5mg pirbuterol hydrochloride and Exirel syrup contains 1.5mg pirbuterol hydrochloride. Also available: EXIREL CAPSULES and SYRUP. 10mg or 15mg administered 3 or 4 times daily. Maximum dose 60mg daily. For children between the ages of 6 and 12 years, the usual syrup dose is 7.5mg/5ml 4 times daily. **Contraindications** Known sensitivity to sympathomimetic agents. Patients receiving non-specific beta adrenergic blocking agents. **Precautions** As with other sympathomimetic agents, Exirel should be used with caution in patients with thyrotoxicosis, coronary artery disease or cardiac arrhythmias. Exirel is not recommended in pregnancy and is not presently indicated for children under 6 years of age. **Side effects** Tremors, headaches, nervousness, insomnia, palpitations have been reported infrequently with Exirel usage. **Warnings** If recommended dose fails to maintain effective relief, patients should be advised to seek immediate medical attention. **Basic NHS cost** Exirel 200 metered dose aerosol (PL0057/0184) £3.60 Exirel capsules 10mg coded Exirel 10 Pfizer Pack of 100 (PL0057/0239) £2.38 Exirel capsules 15mg coded Exirel 15 Pfizer Pack of 100 (PL0057/0230) £3.56 Exirel syrup 150ml (1.5mg/ml) (PL0057/0208) £1.71. **References** 1. MacNee W. et al (1983) Br Med J 287:1169. 1172. 2. Peacock A. et al (1983) Br Med J 287:1178-80. 3. Pitts N. E. et al (1983) in RSM Int Congress & Symposium No 56, London. 4. Moore PF, Constantine JW and Barth WE (1978) J Pharmacol Exp Ther 207 (2)410.


Pfizer

Further information is available on request to Pfizer
London Sandbach, Cheshire

AUGM

EXCELLENT ACTIVITY AGAINST ANOTHER FACET OF ITS OUTSTA

Activity against *Bacteroides*¹



Traditionally, the oral β -lactam antibiotics have possessed little clinically useful activity against anaerobes.

The advent of Augmentin, however, takes *Bacteroides fragilis* within the therapeutic spectrum of oral penicillin-based therapy for the first time.

Prescribing Information

USES: Chest, ENT, Genito-urinary tract, Skin and soft tissue infections.

DOSAGE: Adults and children over 12 years: One Augmentin or Augmentin Dispersible Tablet (375 mg) three times a day. Children 6-12 years: 5 ml Augmentin Junior Suspension (187 mg) three times a day. Children 2-6 years: 5 ml Augmentin Paediatric Suspension (156 mg) three times a day. Children 9 months-2 years: 5 ml half-strength Augmentin Paediatric Suspension (78 mg) three times a day.

Children 3-9 months: 2.5 ml half strength Augmentin Paediatric Suspension (39 mg) three times a day. In severe infections, dosages for patients aged 2 years and over may be doubled. Treatment with Augmentin should not be extended beyond 14 days without review.

CONTRA-INDICATION: Penicillin hypersensitivity.

Superior spectrum of activity

Augmentin is highly active against common pathogens such as streptococci, staphylococci, *H. influenzae*, *E. coli*, *Proteus mirabilis*, *N. gonorrhoea*, *Klebsiella* and *Bacteroides fragilis*.

This high activity is exemplified by a study which showed Augmentin to be an outstanding antibiotic against hospital clinical isolates, including those from wound and genital infections¹:

| | % sensitive or moderately sensitive |
|------------------|-------------------------------------|
| AUGMENTIN | 93% |
| Co-trimoxazole | 80% |
| Ampicillin | 56% |

Confirmed in clinical practice

The excellent clinical results of Augmentin therapy are confirmed in a study involving patients with gynaecological sepsis, intra-abdominal sepsis, cellulitis and bronchopneumonia.³

| Infection | Response |
|---|----------|
| Gynaecological and intra-abdominal infections | 86% |
| Infections involving <i>Bacteroides</i> | 80% |
| Staphylococcal infections | 88% |

Replacement for multiple antibiotic therapies

...in patients suitable for oral therapy, the use of Augmentin may replace combinations such as ampicillin plus metronidazole plus

PRECAUTIONS: Safety in human pregnancy is yet to be established. Dosage need not be reduced in patients with renal impairment, unless dialysis is required.

SIDE-EFFECTS: Uncommon, mainly mild and transitory, eg diarrhoea, indigestion, nausea, vomiting, candidiasis, urticarial and erythematous rashes. If gastrointestinal side-effects occur, they may be reduced by taking Augmentin at the start of meals.

PRESENTATIONS: (Prices correct at October, 1983.) ▼ **Augmentin Tablets and Dispersible Tablets**, each providing 125 mg clavulanic acid with 250 mg amoxycillin. Augmentin Tablets (bottles of 30, 100). Cost per tablet - 29p PL0038/0270. Augmentin Dispersible Tablets (foil wrapped 30, 90). Cost per tablet - 32½p PL0038/0272. ▼ **Augmentin Junior Suspension**. Powder to prepare 100 ml

ENTON

clavulanate-potentiated amoxycillin

BACTEROIDES - WIDENING SPECTRUM.

gentamicin or clindamycin plus tobramycin,
thus simplifying management, avoiding
injections and reducing potential toxicity.^{1,4}

Penicillin-based therapy

Augmentin has been shown to be well tolerated
as would be expected from a penicillin-based
antibiotic.⁵



AUGMENTIN

EXCELLENT ORAL ACTIVITY IN
ANAEROBIC AND AEROBIC INFECTION.

suspension. Each 5 ml provides 62 mg clavulanic acid with 125 mg amoxycillin. Cost per 5 ml dose - 18p PL0038/0274. ▼ Augmentin Paediatric Suspension. Powder to prepare 100 ml suspension. Each 5 ml provides 31 mg clavulanic acid with 125 mg amoxycillin. Cost per 5 ml dose - 14p PL0038/0298. The clavulanic acid is present as potassium clavulanate and the amoxycillin as the trihydrate. All the above presentations are sugar-free formulations.

October 1983

Further information is available on request to the Company.



**Beecham Research
Laboratories**, Brentford, England.

Augmentin and the BRL logo are trade marks.



References: 1. Data published in summary form in: Abbas, A. M. A. et al. Proceedings of the First Augmentin Symposium. Rolinson, G. N. and Watson, A. (eds), Excerpta Medica 1980, pp 173-183. 2. Comber, K. R. et al., Ibid, pp 214-219. 3. Ball, A. P., Mehtar, S. and Watson, A. J. Antimicrob. Chemother. (1982), 10, 67-74. 4. Ball, A. P., Readings in Infection, Medicine International, 1983. 5. O'Grady, F., Proceedings of the Second Augmentin Symposium. Leigh, D. A. and Robinson, O. P. W. (eds), Excerpta Medica 1982, pp 173-183.

The Americans are having fewer heart attacks. Could this become a habit?

Over the last ten years, the Americans have been changing their habits. Millions have stopped smoking altogether. Alcohol consumption has been reduced. Exercise has become the nation's favourite leisure activity.

There is also a significant shift away from foods of a high saturated fat content. Instead, more foods like fish, chicken, fruit and vegetables are being eaten.

For spreads and in cooking, products made from vegetable oils of a high polyunsaturate content are increasingly preferred.

The American Heart Association confirms a real benefit emerging from this healthier way of life: a marked decrease in CHD mortality.*

It can't just be coincidence and, with the current high levels of heart disease in Britain, it's obviously time the British changed to healthier habits.

In all this, Flora margarine can make a positive contribution. Flora is made with pure sunflower oil, so it's high in polyunsaturates.

Eaten as part of a properly balanced diet and combined with a sensible health routine, Flora can help your heart-risk patients enjoy an altogether fitter, healthier lifestyle.



**Flora. High in polyunsaturates.
The margarine that matters.**

*AHA Committee Report - Risk Factors and Coronary Disease (1980)

For further information, please contact: Flora Information Service, 25 North Row, London W1R 2BY.

PIPRIL

INTRAMUSCULAR/INTRAVENOUS – PIPERACILLIN

decisive therapy for hospital infections

Extremely broad spectrum of activity against common and problem pathogens

Synergistic with aminoglycosides without adding to their toxicity

Reassuring penicillin safety for compromised patients, children and infants

Prescribing Information. **Indications:** Pipro is a broad spectrum bactericidal penicillin for the treatment and peri-operative prophylaxis of systematic or local infections caused by sensitive organisms. **Dosage:** Adult patients with normal renal function should receive 4-8g daily in divided doses for mild or uncomplicated infections. In serious or life-threatening infections 12-16g daily in divided doses. For peri-operative prophylaxis 2g just prior to surgery followed by at least two doses of 2g at four or six hour intervals. Patients with renal insufficiency may need dosage reduction – see Data Sheet. Children 2 months to 12 years of age: 100-300mg/kg daily in three or four divided doses. Neonates and infants under two months of age: 100-300mg/kg daily in two equally divided doses. **Contra-indications:** Penicillin or severe cephalosporin hypersensitivity. **Precautions:** Safety for use in pregnant or lactating women has not yet been established. **Side effects:** Uncommon and typical of injectable penicillins. **Administration:** Pipro is presented as 1g or 2g vials, 4g infusion bottles and 4g infusion packs containing piperacillin as piperacillin sodium. See Data Sheet or package leaflet for full details of preparation and administration. **Product Licence No:** 0095/0073 **Basic NHS Price:** 1g vial £2.63, 2g vial £5.20, 4g vial £10.29, 4g infusion pack £10.96. Further information is available on request.



Lederle Laboratories

Division of Cyanamid of Great Britain Ltd., Fareham Road, Gosport, Hants PO13 0AS (Tel: 0329-236131)

PIPRIL is a trade mark

'Fenbid' Arthritis th

Conventional arthritis therapy can result in large variations in drug serum levels. If the levels fall too low an adequate effect may not be achieved. If they are too high, side effects are more likely.

'Fenbid' is a sustained-release preparation of



PRESCRIBING INFORMATION. **Presentation** — 'Fenbid' Capsules, PL 0002/0111, each containing 300 mg ibuprofen in sustained-release form. 120, £8.40. **Indications** — Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, other seronegative (non-rheumatoid) arthropathies; acute periarthritis disorders; relief of mild to moderate pain in sprains, strains, low back pain, dysmenorrhoea; dental and post-operative pain. **Dosage** — Adults and children over 12 years: Start with 2 capsules night and morning. May be increased to 3 capsules b.d. until acute phase is controlled. Maintenance: 1 or 2 b.d. Do not chew or suck capsules or pellets. Capsule may be opened and pellets mixed with soft food. **Contra-indication** — Active peptic ulceration. **Cautions** — Gastrointestinal disease (but may be tolerated in patients with intolerance to other anti-rheumatic drugs); actual or history of bronchial asthma. Monitor

erapy on the level.

ibuprofen formulated to reduce these highs and lows.
'Fenbid' provides effective relief of symptoms. And is at least as well tolerated as conventional ibuprofen.

Effective and well tolerated; a dosage that is simple and convenient. Arthritis therapy on the level.



Fenbid

SUSTAINED RELEASE IBUPROFEN



2x300mg caps bid

prothrombin time daily for first few days in patients on anticoagulant therapy. Pregnancy and lactation. **Adverse reactions** — Gastrointestinal upsets, rash, headache, nervousness, tinnitus, oedema. Rarely gastrointestinal haemorrhage. Blurred vision, toxic amblyopia, thrombocytopenia, oliguric renal failure reversed on stopping treatment. **Overdosage** — Treatment: maintain normal blood pressure, correct electrolyte imbalance; consider emesis in children and gastric lavage in adults; symptomatic measures. **Legal category** — POM. 2.11.83. Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY. 'Fenbid' is a trade mark. © 1983 Smith Kline & French Laboratories Limited EN-AD23.

SK&F

Gastrozepin is a selective antimuscarinic agent which provides balanced control of gastric secretion without markedly affecting other peripheral receptor sites. This gastro-selective action means that, in practice, Gastrozepin is a well-tolerated drug which heals peptic ulcers.

Gastrozepin DOES NOT . . .

- rely on acid reduction alone
- rely on pepsin reduction alone
- rely on mucosal protection alone
- profoundly affect intragastric pH

Gastrozepin DOES . . .

- relieve daytime pain
- relieve night-time pain
- reduce antacid intake
- heal peptic ulcers with one 50 mg tablet b.d.


For the treatment of peptic ulcer

Twice daily

GASTRO SELECTIVE

Gastrozepin®

pirenzepine



The gastro-selective anti-secretory

Prescribing Information: Presentation: White tablets each containing 50 mg of pirenzepine dihydrochloride scored on one face with "G" on one side of the score, and "50" on the other. The obverse is impressed with the symbol . Uses: Gastrozepin is indicated in the treatment of gastric and duodenal ulcers. Dosage: 50 mg at bedtime and in the morning before meals. In severe cases the total daily dose may be increased to 150 mg in divided doses. Continuous therapy may be recommended for up to three months. Contra-indications, Warnings etc: Interaction with sympathomimetics and monoamine oxidase inhibitors and Gastrozepin is a teratogen in animals. Gastrozepin is not recommended during pregnancy although in animal

experiments no teratogenic effects were noted. Breast milk concentration after therapeutic doses is unlikely to affect the infant. Side effects: occasionally transitory dry mouth and accommodation difficulty may occur. Treatment of overdosage: entirely symptomatic. There is no specific antidote. Basic NHS price: 50 mg tablets, 60 £20.50. Product Licence No.: 50 mg tablets, PL0014/0260.

Further information is available on request
The Boots Company PLC Nottingham

Gastrozepin® Trade Mark

Du Pont Pharmaceuticals

A more effective strong analgesic



- Low incidence of nausea and vomiting^{1,2,3}
- Demonstrated ceiling effect to respiratory depression⁴
- No significant adverse clinical effect on the cardiovascular system^{5,6,7}
- Low incidence of psychotomimetic effects^{2,8,9,10}
- Not a Controlled Drug

NEW
NUBAIN[®]
nabuphine hydrochloride

• Thus, nabuphine appears to offer a useful alternative to morphine in patients with moderate to severe pain**

Erick JF and Heit RC. Nabuphine Drug Evaluation. Drugs 1983 26(19):211

*Copies of complete article available from Du Pont Pharmaceuticals
Wedgwood Way, Stevenage, Herts SG1 4QH Tel: Stevenage (0438) 734549



Prescribing Information

Presentation:
An ampoule containing a clear colourless sterile aqueous solution of 20mg nalbuphine hydrochloride in 2ml.

Uses:
Nubain injection is indicated for the relief of moderate to severe pain. It can also be used for pre- and post-operative analgesia.
Dosage and Administration:
Nubain injection may be administered subcutaneously, intramuscularly or intravenously. The usual recommended dosage is 10mg-20mg for a 70kg individual. The dosage should be adjusted according to the severity of pain, physical status of the patient and other medications the patient may be receiving.

Contra-indications, Warnings and Precautions:
Contra-indications: Nubain should not be administered to patients who are hypersensitive to it.
Warnings: Drug dependence: Nubain has low abuse potential. However, caution should be observed in prescribing it for emotionally unstable patients or for patients with a history of opioid abuse. When Nubain is selected for the control of chronic pain, its suggested prolonged activity may delay the need for larger or more frequent doses. Abrupt discontinuation of Nubain following prolonged use has been followed by symptoms of opioid withdrawal. Use in ambulatory patients: Nubain may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. Therefore, Nubain should be administered with caution to ambulatory patients who should be warned to avoid such hazards. Use in children: Because clinical experience in children under the age of 12 is limited, the administration of Nubain in this age group is not recommended.
Use in pregnancy: Safe use of Nubain in pregnancy (including labour) has not been established. Although animal studies have not revealed teratogenic or embryotoxic effects, nalbuphine should only be administered to pregnant women when, in the judgement of the physician, the potential benefits outweigh the possible hazards. Nubain should be used to provide analgesia in patients with head injury and increased intracranial pressure only when essential, and then should be administered with extreme caution. Patients receiving an opioid analgesic, general anaesthetic, phenothiazine or other tranquilizer, sedative, hypnotic or other CNS depressant (including alcohol) concomitantly with Nubain may exhibit an additive effect. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

Precautions: Caution should be observed in administering the drug to patients with impaired respiration, or with other medications which produce respiratory depression. In the presence of bronchial asthma, uraemia, severe infection, cyanosis or respiratory obstruction, Nubain should be administered with caution and in reduced doses. Safety for use in myocardial infarction has not been established. Nubain should be used with caution and administered in reduced amounts in patients with impaired renal or hepatic function.

Adverse Effects:
The most frequently seen reaction to Nubain is sedation. Less frequent are sweating, nausea, vomiting, dizziness, dry mouth, vertigo and headache. Rarely seen are CNS effects such as nervousness, depression, confusion and dysphoria. Also reported have been hypertension, bradycardia, tachycardia, dyspepsia, gastrointestinal cramps, itching, urticaria, speech difficulty, blurred vision and flushing.

Management of overdosage. The immediate intravenous administration of Narcan (naloxone hydrochloride) is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated.

Pharmaceutical Precautions:

Protect from light. Store at room temperature (15-30°C).

Legal Category: Prescription Only Medicine.

Package Quantities: Nubain ampoules each containing 2ml are supplied in boxes of 10 ampoules.

Further Information: Nil.

Product Licence Number: 4524/0003.

Basic NHS Cost: £11.60 per box of 10x2ml ampoules.

Date of Preparation: August 1983.

References

1. Fregen R, Caldwell N. Acute intravenous premedication with nalbuphine. *Anesth Analg* 1977;56:808-12.
2. Janczak D, Mansky P. Evaluation of nalbuphine for abuse potential. *Clin Pharmacol Ther* 1972;13:78-90. 3. Data on file, Du Pont Pharmaceuticals (UK) Ltd.
4. Romagnoli A, Keats AS. Ceiling effect for respiratory depression by nalbuphine. *Clin Pharmacol Ther* 1980;27:478-85.
5. Romagnoli A, Keats AS. Comparative haemodynamic effects of nalbuphine and morphine in patients with coronary artery disease. *Bull Tex Heart Inst* 1978;5(1):19-24.
6. Lake C et al. Cardiovascular effects of nalbuphine in patients with coronary or valvular heart disease. *Anesthesiology* 1982;57:498-503.
7. Leg G et al. Haemodynamic effects of morphine and nalbuphine in acute myocardial infarction. *Clin Pharmacol Ther* 1981;29(5):576-81.
8. Stansbrough J. Evaluation of nalbuphine: Efficacy and safety in the management of chronic pain associated with advanced malignancy. *Curr Ther Res* 1982;31(3):393-401.
9. Houde RW et al. Annual Report of the Analgesic Studies Section of the Memorial Sloan-Kettering Cancer Centre 1976.
10. Tammisto T, Tigerstedt I. Comparison of the Analgesic Effects of Intravenous Nalbuphine and Pentazocine in Patients with Postoperative Pain. *Acta Anaesth Scand* 1977;21:390-394.

Further information is available on request from the Company.
Du Pont (UK) Ltd, Pharmaceuticals, Wedgwood Way, Stevenage, Herts SG1 4QN.
Nubain® is a registered trademark of E.I. du Pont de Nemours & Co. Inc.

ROYAL POSTGRADUATE MEDICAL SCHOOL

in collaboration with

GLAXO GROUP RESEARCH LIMITED

BASIC SCIENCE IN GASTROENTEROLOGY SYMPOSIA

Seventh Symposium of the Series

GASTROINTESTINAL CARCINOGENESIS

London — 24 April 1984

Organisers: J M Polak, S R Bloom, N A Wright, A G Butler

Invited speakers include:

D Britton, UK; J Jass, UK; R Riddell, USA; W W L Chang, USA; M Lipkin, USA; J P Sunter, UK; P Correa, USA; B Morson, UK; J Weisburger, USA; M Hill, UK; R R Peto, UK; R C N Williamson, UK; C S Potten, UK

Topics include:
Epidemiology, Chemical Carcinogenesis, Cell Proliferation, Environmental Factors, Dysplasia, Pre-cancerous Lesions, Atrophic Gastritis

Registration and Lunch — £10.00

For further details and Application Form please contact:

**A G Butler,
Medical Division, Glaxo Group
Research Ltd., Ware, Herts. SG12 0DJ.
Telephone No. 0920 3993**


**Closing date for applications:
13 April 1984.**

For the hurting hip

To your patient, arthritis means pain and the right treatment is that which brings quick and sustained relief.

Froben brings the pain of arthritic joints under control within hours and maintains that control for as long as is needed. For months. If necessary, for years.

Powerful, yet well tolerated, Froben provides the sustained, consistent relief of pain which must be the right treatment for arthritis. With Froben, the treatment is right from the start.



Start with

Froben

flurbiprofen

the undoing of arthritic pain

Prescribing Information

PRESENTATION: Sugar-coated tablets, each containing either 50 or 100mg of flurbiprofen. **USES:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **DOSAGE:** 150 to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms or diseases of recent origin, or during acute exacerbations, the total daily dose may be increased to 300mg in divided doses. **CONTRA-INDICATIONS,** **WARNINGS:** Froben should not be given to patients with peptic ulcer disease, diarrhoea, history of bowel disease, or to patients with a history of anaphylactic or hypersensitivity reactions to non-steroidal anti-inflammatory drugs or other non-steroidal anti-inflammatory agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. Froben may prolong bleeding time and cause fluid retention. Use with caution where renal function is impaired. **Side effects:** Dyspepsia, heartburn and headache are the commonest encountered. Gastrointestinal haemorrhage, diarrhoea, mouth ulcers, peptic ulceration and skin rashes have been reported. Very rarely cholestatic jaundice and blood dyscrasias have been reported but a direct causal relationship has not been established. **Drug interactions:** The effect of anti-coagulants may be increased and oral diuretics may be reduced. **Treatment of Overdose:** Gastric lavage and, if necessary, correction of serum electrolytes. There is no specific antidote. **BASIC NHS PRICE:** 50mg tablets, 100 £2.25; 100mg tablets, 100 £3.65. **PRODUCT LICENCE No:** 50mg tablets, PL0014/0167; 100mg tablets, PL0014/0168.



The Boots Company PLC, Nottingham, England.

Further information available on request



*Guard against
infection in surgery*

Glaxo

Hospital antibiotics

clin

AVIATION MEDICINE

Richard M Harding & F John Mills


This authoritative and highly readable account of the little known specialty of aviation medicine will interest both general readers and those interested in it as a career. Comprehensive information on the management of airline passengers with particular medical conditions before, during, and after flight will help doctors faced with deciding whether or not their patient is fit to fly and with coping with a medical emergency in the air while themselves passengers on board an aircraft. The chapters on the problems of altitude, acceleration, the function of the special senses in flight, special forms of flight, and aviation psychology describe clearly and precisely the physiological and behavioural effects that flight imposes on man.

Price: Inland £5.50;
Overseas £7.50/USA\$13.00
(Inland £5.00;
Overseas £7.00/USA\$12.00 to
BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller





The cost of living has never looked so good.

Human insulin has always been seen as an outstandingly pure,¹ less immunogenic form of insulin² than that which comes from the pancreas of pigs and cattle.

It has, however, been seen as expensive.

In fact, Humulin costs less than

the most widely prescribed porcine insulins.

The price? Just £6.44 for 100 i.u.

You see, Humulin uses genetic engineering and the techniques of recombinant DNA technology as the method of manufacture.

Which means it's completely

independent of pork and beef prices.

Thus, it can be produced economically, and in large quantities for years to come.

Humulin
Human Insulin (crb)
THE HUMAN WAY TO TREAT DIABETES

ABC OF COMPUTING

Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants to know how computers can contribute to his practice of medicine.


Price: Inland £5.75;
Overseas £8.00*; USA \$14.00*
(Inland £5.25;
Overseas £7.50*; USA \$13.00*
to BMA members)

**including air mail postage*

Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



ABC OF HEALTHY TRAVEL

ERIC WALKER GLYN WILLIAMS

With more people travelling abroad each year the health problems of travellers, both abroad and on their return, assume increasing importance. Travellers may be at hazard from the environment, their lifestyles, and their lack of familiarity with foreign customs. Doctors need to be able to advise their travelling patients and to be aware of the—sometimes potentially serious— infections that may not become apparent until the traveller has return home. In the ABC of Healthy Travel in the *BMJ* Dr Eric Walker and Dr Glyn Williams described the problems facing the traveller, the immunisations he needs, the infections he may bring home; suggested ways of preventing and treating illness abroad; listed sources of up to date information; and reviewed recent advice on malaria prophylaxis. These articles have been collected into a book to provide the busy practitioner with a practical guide to advising travellers and managing their illnesses.


Price: Inland £4.00;
Overseas £6.00/USA\$10.50
(Inland £3.50;
Overseas £5.50/USA\$9.50
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



A major publishing event
in the field of
drug information - the
new edition of ...

MARTINDALE

The Extra Pharmacopoeia

The world's most comprehensive source of drug information in a single volume

TWENTY-EIGHTH EDITION

*Prepared by the editorial staff of
The Pharmaceutical Society of Great Britain,
and edited by James E. F. Reynolds*

2056 pages 275 x 222 mm £60.00
0 85369 160 6 Clothbound
Published December 1982

● Provides an accurate and concise summary of the properties, actions, and uses of drugs and medicines in clinical use throughout the world. The new Martindale contains:

- More than 5100 monographs on drugs and ancillary substances
- More than 50,000 drug names, synonyms, codes, and preparation names
- More than 3000 manufacturers' names and addresses throughout the world
- More than 57,000 relevant abstracts and references

- All information has been evaluated by the expert editorial staff of The Pharmaceutical Society of Great Britain
- This new edition has been completely revised, and contains more information than in any other previous edition
- International coverage still further extended, so that Martindale covers all drugs used clinically in most countries of the world

Contents

PART 1 — Monographs on Drugs and Ancillary Substances: Information on all the main substances of medicinal and pharmaceutical interest, arranged in chapters (1671 pages).

PART 2 — Supplementary Drugs and Ancillary Substances: Information on new drugs, obsolescent drugs, and miscellaneous substances (99 pages).

PART 3 — Formulas of Proprietary Medicines: Composition of medicines sold over-the-counter in the United Kingdom (17 pages).

Directory of Manufacturers: Names and addresses of manufacturers mentioned in the text.

Index to Clinical Uses of drugs mentioned in the text of Parts 1 and 2.

Index to Martindale Identity Numbers: Links monographs with Martindale Online.

General Index to drug names, medicinal preparations, and miscellaneous substances (about 50,000 entries).

Preface: Provides terms of reference and tables of contents; nomenclature of chemical radicals; abbreviations; atomic weights; dissociation constants; body-surface area calculations; SI units; millimoles and milliequivalents; Imperial and other equivalents.

THE PHARMACEUTICAL PRESS
1 Lambeth High Street
London SE1 7JN, England

Copies of Martindale may be obtained through your local medical bookseller or, in any case of difficulty, direct from the publishers.

ABC OF HYPERTENSION

Hypertension is a common disorder that is easily detected. But it may be deceptively simple: the measurement of blood pressure, interpretation of the results, and the decisions that follow need to be based on a comprehensive knowledge of recent advances. These illustrated articles on blood pressure measurement, reduction and management provide a practical guide for general practitioners and others concerned with hypertension.

Price: Inland £4.00
Overseas £6.00/USA\$10.50
(Inland £3.50; Overseas £5.50/USA\$9.50
to BMA members)
Despatched by air overseas
Payment must be enclosed with order

Order your copy now

From: The Publisher
British Medical Journal, BMA House,
Tavistock Square, London WC1H 9JR
or any leading bookseller

A NEW COURSE FOR THE MRCP


**Now completely rewritten and updated
with new clinical slides, X-rays and
ECG's included.**

**Write for full details of this essential
correspondence course for PART I and
PART II**

J. ARNOLD
(Correspondence Courses)
19 VILLAGE WAY,
LONDON SE21 7AN

IN HYPERTENSION AND ANGINA

Put it all together...



...in one tablet daily

TENORMIN

fits the profile of the ideal beta blocker
in hypertension and angina

Tenormin® Prescribing notes:

Presentation: Tenormin® tablets containing atenolol 100 mg are round, bi-convex, orange and film coated. **Uses:** Management of hypertension and angina pectoris. **Dosage:** Hypertension: One tablet daily. Angina: 100 mg daily in single or divided doses. **Contraindications:** Heart block. Co-administration with verapamil. **Precautions:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia and pregnancy. Clonidine withdrawal. **Side Effects:** Coldness of extremities and muscular fatigue. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta blockers—consider discontinuance if they occur. Cessation of therapy with beta blockers should be gradual. **Pack size and Basic NHS cost:** 'Tenormin' 28's £7.05. **Product Licence Number:** 'Tenormin' 0029/0122.

Full prescribing information is available on request to the Company

Stuart Pharmaceuticals Ltd
Carr House, Carrs Road
Cheadle, Cheshire SK8 2EG
'Tenormin' is a trademark.

